FDA Grants First Priority Voucher Approval to Augmentin XR

By Fran KritzThe FDA approved Augmentin XR (amoxicillin-clavulanate potassium) to be manufactured by USAntibiotics under the Commissioner’s National Priority Voucher (CNPV) pilot program, marking the first time since the program was announced in June that a drug has been approved though the new review pathway.figure img { width:100% !important; } figcaption { padding: 5px; background: transparent; word-wrap: normal; text-align: center; font-size:10px; line-height: 12px; }©McMahon Grou